Home > Insider Trading > Filing (0001209191-18-029534)

Filing Details

Accession Number:: 0001209191-18-029534
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-05-11 16:15:21
Reporting Period:: 2018-05-09

Accepted Time:: 2018-05-11 16:15:21
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
818686	Teva Pharmaceutical Industries Ltd	TEVA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1258394	Roberto Mignone	C/O Teva Pharmaceutical Industries Ltd. 5 Basel Street Petach Tikva L3 4951033		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Acquisiton	2018-05-09	500,000	$19.21	1,250,000	No	4	P	Indirect	[see footnote]
Ordinary Shares	Acquisiton	2018-05-10	250,000	$19.32	1,500,000	No	4	P	Indirect	[see footnote]

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	[see footnote]
No	4	P	Indirect	[see footnote]

Footnotes

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
The price reported in Column 4 is a weighted average price. These Ordinary Shares were purchased in multiple transactions at prices ranging from $18.99 to $19.30, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of Ordinary Shares purchased at each separate price.
The 1,500,000 Ordinary Shares disclosed in Table I of this Form 4 are held of record by Swiftcurrent Partners, L.P. and Swiftcurrent Offshore Master, Ltd. (the "Funds"). Bridger Management, LLC is the investment adviser to the Funds and Mr. Mignone is the manager of Bridger Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone may be deemed to beneficially own the Ordinary Shares held of record by the Funds. Mr. Mignone disclaims beneficial ownership of the Ordinary Shares held of record by the Funds except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone is the beneficial owner of the Ordinary Shares held of record by the Funds for purposes of Section 16, or for any other purpose.
The price reported in Column 4 is a weighted average price. These Ordinary Shares were purchased in multiple transactions at prices ranging from $19.2450 to $19.3700, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of Ordinary Shares purchased at each separate price.